Adagene Inc. (FRA:978)

Market Cap	154.23M +92.1%
Revenue (ttm)	87.88K -87.3%
Net Income	-25.45M
EPS	-0.55
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	3.500
Previous Close	3.460
Day's Range	3.500 - 3.500
52-Week Range	1.180 - 3.620
Beta	n/a
RSI	63.34
Earnings Date	Mar 31, 2026

About Adagene

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 138
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 978

Financial Performance

In 2024, Adagene's revenue was $103,204, a decrease of -99.43% compared to the previous year's $18.11 million. Losses were -$33.42 million, 76.4% more than in 2023.

Financial numbers in USD